# BioAtla, Inc.: financial statements, quarterly

BCAB · OTC · CIK 1826892 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bcab.md) · [Financials](/companies/bcab/financials.md) · [Filings](/companies/bcab/filings.md) · [Insiders](/companies/bcab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bcab/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-23-060389.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [28.4](/filings/0000950170-24-123506.md) | [22.7 d](/filings/0000950170-25-046217.md) | [18.9](/filings/0000950170-25-064594.md) | [16.2](/filings/0000950170-25-105220.md) | [16.4](/filings/0001193125-25-280435.md) | [11.7 d](/filings/0001193125-26-134499.md) | [12.4](/filings/0001193125-26-226631.md) | [13.7](/filings/0001193125-26-349542.md) | [9.5](/filings/0001193125-25-280435.md) | [8.0 d](/filings/0001193125-26-134499.md) | [4.6](/filings/0001193125-26-226631.md) | [3.3](/filings/0001193125-26-349542.md) |
| Operating income | $m | [(35.0)](/filings/0000950170-24-123506.md) | [(28.5) d](/filings/0000950170-25-046217.md) | [(24.5)](/filings/0000950170-25-064594.md) | [(22.0)](/filings/0000950170-25-105220.md) | [(11.3)](/filings/0001193125-25-280435.md) | [(16.2) d](/filings/0001193125-26-134499.md) | [(17.6)](/filings/0001193125-26-226631.md) | [(18.6)](/filings/0001193125-26-349542.md) | [(13.8)](/filings/0001193125-25-280435.md) | [(9.3) d](/filings/0001193125-26-134499.md) | [(9.3)](/filings/0001193125-26-226631.md) | [0.2](/filings/0001193125-26-349542.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(33.3)](/filings/0000950170-24-123506.md) | [(26.9) d](/filings/0000950170-25-046217.md) | [(23.2)](/filings/0000950170-25-064594.md) | [(21.1)](/filings/0000950170-25-105220.md) | [(10.6)](/filings/0001193125-25-280435.md) | [(14.9) d](/filings/0001193125-26-134499.md) | [(15.3)](/filings/0001193125-26-226631.md) | [(18.7)](/filings/0001193125-26-349542.md) | [(15.8)](/filings/0001193125-25-280435.md) | [(9.8) d](/filings/0001193125-26-134499.md) | [(6.3)](/filings/0001193125-26-226631.md) | [0.5](/filings/0001193125-26-349542.md) |
| Diluted EPS | $ per share | [(0.70)](/filings/0000950170-24-123506.md) | not reported | [(0.48)](/filings/0000950170-25-064594.md) | [(0.44)](/filings/0000950170-25-105220.md) | [(0.22)](/filings/0001193125-25-280435.md) | not reported | [(13.16)](/filings/0001193125-26-226631.md) | [(15.99)](/filings/0001193125-26-349542.md) | [(0.27)](/filings/0001193125-25-280435.md) | not reported | [(4.22)](/filings/0001193125-26-226631.md) | [0.27](/filings/0001193125-26-349542.md) |
| Basic EPS | $ per share | [(0.70)](/filings/0000950170-24-123506.md) | not reported | [(0.48)](/filings/0000950170-25-064594.md) | [(0.44)](/filings/0000950170-25-105220.md) | [(0.22)](/filings/0001193125-25-280435.md) | not reported | [(13.16)](/filings/0001193125-26-226631.md) | [(15.99)](/filings/0001193125-26-349542.md) | [(0.27)](/filings/0001193125-25-280435.md) | not reported | [(4.22)](/filings/0001193125-26-226631.md) | [0.27](/filings/0001193125-26-349542.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [141](/filings/0000950170-23-060389.md) | [111](/filings/0000950170-25-046217.md) | [80.6](/filings/0000950170-24-059757.md) | [61.7](/filings/0000950170-24-094164.md) | [56.5](/filings/0000950170-24-123506.md) | [49.0](/filings/0001193125-26-134499.md) | [32.4](/filings/0000950170-25-064594.md) | [18.2](/filings/0000950170-25-105220.md) | [8.3](/filings/0001193125-25-280435.md) | [7.1](/filings/0001193125-26-349542.md) | [2.0](/filings/0001193125-26-226631.md) | [1.5](/filings/0001193125-26-349542.md) |
| Current assets | $m | [148](/filings/0000950170-23-060389.md) | [116](/filings/0000950170-25-046217.md) | [86.4](/filings/0000950170-24-059757.md) | [66.5](/filings/0000950170-24-094164.md) | [60.6](/filings/0000950170-24-123506.md) | [51.2](/filings/0001193125-26-134499.md) | [37.5](/filings/0000950170-25-064594.md) | [20.6](/filings/0000950170-25-105220.md) | [9.7](/filings/0001193125-25-280435.md) | [8.0](/filings/0001193125-26-349542.md) | [3.1](/filings/0001193125-26-226631.md) | [4.3](/filings/0001193125-26-349542.md) |
| Total assets | $m | [151](/filings/0000950170-23-060389.md) | [120](/filings/0000950170-25-046217.md) | [89.2](/filings/0000950170-24-059757.md) | [68.6](/filings/0000950170-24-094164.md) | [62.2](/filings/0000950170-24-123506.md) | [52.4](/filings/0001193125-26-134499.md) | [38.3](/filings/0000950170-25-064594.md) | [27.1](/filings/0000950170-25-105220.md) | [15.9](/filings/0001193125-25-280435.md) | [13.8](/filings/0001193125-26-349542.md) | [8.6](/filings/0001193125-26-226631.md) | [9.5](/filings/0001193125-26-349542.md) |
| Current liabilities | $m | [35.6](/filings/0000950170-23-060389.md) | [28.3](/filings/0000950170-25-046217.md) | [19.3](/filings/0000950170-24-059757.md) | [17.5](/filings/0000950170-24-094164.md) | [19.5](/filings/0000950170-24-123506.md) | [14.5](/filings/0001193125-26-134499.md) | [16.0](/filings/0000950170-25-064594.md) | [16.6](/filings/0000950170-25-105220.md) | [18.0](/filings/0001193125-25-280435.md) | [21.9](/filings/0001193125-26-349542.md) | [20.7](/filings/0001193125-26-226631.md) | [21.0](/filings/0001193125-26-349542.md) |
| Total liabilities | $m | [56.7](/filings/0000950170-23-060389.md) | [49.0](/filings/0000950170-25-046217.md) | [39.5](/filings/0000950170-24-059757.md) | [37.3](/filings/0000950170-24-094164.md) | [39.3](/filings/0000950170-24-123506.md) | [38.2](/filings/0001193125-26-134499.md) | [37.7](/filings/0000950170-25-064594.md) | [43.9](/filings/0000950170-25-105220.md) | [47.1](/filings/0001193125-25-280435.md) | [50.0](/filings/0001193125-26-349542.md) | [45.9](/filings/0001193125-26-226631.md) | [45.7](/filings/0001193125-26-349542.md) |
| Shareholders' equity | $m | [94.7](/filings/0000950170-23-060389.md) | [70.7](/filings/0000950170-25-046217.md) | [49.7](/filings/0000950170-24-059757.md) | [31.4](/filings/0000950170-24-094164.md) | [23.0](/filings/0000950170-24-123506.md) | [14.3](/filings/0001193125-26-134499.md) | [0.5](/filings/0000950170-25-064594.md) | [(16.7)](/filings/0000950170-25-105220.md) | [(31.2)](/filings/0001193125-25-280435.md) | [(36.2)](/filings/0001193125-26-349542.md) | [(37.3)](/filings/0001193125-26-226631.md) | [(36.2)](/filings/0001193125-26-349542.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(27.3) d](/filings/0000950170-24-123506.md) | [(29.9) d](/filings/0000950170-25-046217.md) | [(30.8)](/filings/0000950170-25-064594.md) | [(19.2) d](/filings/0000950170-25-105220.md) | [(5.1) d](/filings/0001193125-25-280435.md) | [(16.8) d](/filings/0001193125-26-134499.md) | [(16.3)](/filings/0001193125-26-226631.md) | [(14.1) d](/filings/0001193125-26-349542.md) | [(9.9) d](/filings/0001193125-25-280435.md) | [(7.9) d](/filings/0001193125-26-134499.md) | [(5.3)](/filings/0001193125-26-226631.md) | [(0.4) d](/filings/0001193125-26-349542.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.5](/filings/0000950170-23-060389.md) | [47.6](/filings/0000950170-24-059757.md) | [47.7](/filings/0000950170-24-094164.md) | [47.8](/filings/0000950170-24-123506.md) | [48.1](/filings/0000950170-25-064594.md) | [48.2](/filings/0000950170-25-105220.md) | [48.3](/filings/0001193125-25-280435.md) | [1.2](/filings/0001193125-26-226631.md) | [1.2](/filings/0001193125-26-349542.md) | [58.7](/filings/0001193125-25-280435.md) | [1.5](/filings/0001193125-26-226631.md) | [1.7](/filings/0001193125-26-349542.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,315,301 at 2021-08-13, from the cover of the [10-Q filed 2021-08-13](/filings/0000950170-21-001443.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.